GlassScriptPhysician profile
Gregory J Colman
NPI 1003884925
$2,239.62
in general payments reported to CMS, 2019-2025
25 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $215 · 2021: $378 · 2022: $613 · 2023: $237 · 2024: $273 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.36 | 2020-2025 | |
| Janssen Biotech, INC. | $221.08 | 2021-2024 | Tremfya |
| Galderma Laboratories, L.P. | $191.33 | 2019-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $176.43 | 2020-2025 | |
| Genzyme Corporation | $171.94 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $153.06 | 2019-2022 | |
| Ucb, INC. | $153.02 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $145.00 | 2020-2023 | Dupixent |
| Sandoz INC. | $106.26 | 2019-2020 | |
| Leo Pharma INC. | $75.38 | 2022-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $58.10 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.05 | 2019-2022 | |
| Epi Health, LLC | $47.99 | 2019 | |
| Incyte Corporation | $45.16 | 2022-2024 | Opzelura |
| Vyne Pharmaceuticals INC. | $41.35 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.93 | 2023 | Otezla |
| Organon LLC | $30.54 | 2025 | Vtama |
| Kyowa Kirin, INC. | $23.62 | 2024 | Poteligeo |
| Lilly USA, LLC | $23.59 | 2019 | |
| Almirall LLC | $21.11 | 2022 | |
| Mission Pharmacal Company | $18.85 | 2019 | |
| Celgene Corporation | $18.75 | 2019 | |
| Pfizer INC. | $18.49 | 2022 | |
| Mayne Pharma Commercial LLC | $18.15 | 2021 | |
| Smith+Nephew, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Colman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.